Explanatory Note
This Amendment No. 1 to Schedule 13G (this “Amendment No. 1”) is filed by Mallinckrodt plc (“Mallinckrodt”) and amends the statement on Schedule 13G originally filed on February 11, 2019. On November 4, 2019, Mallinckrodt plc completed the sale of its wholly-owned subsidiary BioVectra Inc. Mallinckrodt plc does not own any shares of common stock of the Issuer, but may have been deemed to beneficially own the shares held by BioVectra Inc. prior to such sale.
Item 1. | (a) Name of Issuer: |
Oncolix, Inc.
(b) Address of Issuer’s Principal Executive Offices:
14405 Walters Road, Suite 780, Houston, Texas 77014
Items 2 | (a) Name of Person Filing: |
Mallinckrodt plc
(b) Address of Principal Business Office or, if None, Residence:
Mallinckrodt plc – 3 Lotus Park, The Causeway, Staines-Upon-Thames, Surrey TW18 3AG, United Kingdom
(c) Citizenship:
Mallinckrodt plc – Ireland
(d) Title of Class of Securities:
Common Stock, $0.0001 par value per share
(e) CUSIP Number:
00773M106
| (a) | Amount beneficially owned: 0 shares |
| (c) | Number of shares to which such Reporting Persons have: |
| (i) | Sole power to vote or to direct the vote: 0 |
| (ii) | Shared power to vote or to direct the vote: 0 |
| (iii) | Sole power to dispose or to direct the disposition of: 0 |
| (iv) | Shared power to dispose or to direct the disposition of: 0 |